Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091684 | 0.83 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL6982170 | 0.80 | MAPT (0.51) | ALDH1A1MEN1KMT2ALMNAHTT | |
| SCHEMBL5829506 | 0.79 | MAPT (0.56) | ALDH1A1SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL6984451 | 0.79 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL6985873 | 0.79 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL11669933 | 0.78 | MAPT (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4334179 | 0.78 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL6986648 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL27372203 | 0.76 | ALDH1A1 (0.97) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL13957608 | 0.74 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1292585-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | SQLE, CYP17A1, ACOX1 | ALDH1A1 1026/4885SMN1; SMN2 4321/4885MEN1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.